» Articles » PMID: 16955819

Recurrence Rate, Clinical Outcome, and Cellular Proliferation Indices As Prognostic Indicators After Incomplete Surgical Excision of Cutaneous Grade II Mast Cell Tumors: 28 Dogs (1994-2002)

Overview
Date 2006 Sep 8
PMID 16955819
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

The objectives of this study were to determine local recurrence rate, clinical outcome, and prognostic value of the number of argyrophylic nucleolar organizer regions (AgNORs), presence of proliferating cell nuclear antigen (PCNA), and number of Ki-67-positive nuclei after incomplete surgical excision of canine cutaneous grade II mast cell tumors (MCTs). This retrospective study included 30 MCTs in 28 dogs. Medical records were examined and follow-up information was obtained from owners and referring veterinarians. Only cases in which excision was incomplete and no anvcillary therapy (other than prednisone) for MCT was given were included. Paraffin-embedded tumor tissues were retrieved for AgNORs, PCNA, and Ki-67 staining. Median follow-up time was 811.5 days. Seven (23.3%) tumors recurred locally. Median time to local recurrence was not reached with a mean of 1,713 days. The estimated proportions of tumors that recurred locally at 1, 2, and 5 years were 17.3, 22.1, and 33.3%, respectively. Eleven (39.3%) dogs developed MCTs at other cutaneous locations. Median progression-free survival was 1,044 days. Median overall survival was 1,426 days. The combination of Ki-67 and PCNA scores was prognostic for local recurrence (P = .03) and development of local recurrence was prognostic for decreased overall survival (P = .04). Results suggest that a minority of incompletely excised MCTs recur. Therefore, ancillary local therapies may not always be necessary. However, local recurrence can negatively affect survival of the affected dogs. Cellular proliferation indices may indicate the likelihood of MCT recurrence after incomplete excision.

Citing Articles

Evaluation of the Effect of a New Skin Fixation Technique to Avoid Shrinkage of Skin Samples Obtained from Canine Cadavers.

Zorgevica-Pockevica L, Kuzhel N, Kerziene S, Vincenti S Animals (Basel). 2024; 14(19).

PMID: 39409740 PMC: 11482562. DOI: 10.3390/ani14192791.


Scar revision for incompletely or narrowly excised cutaneous mast cell tumors in dogs.

Grimes J, Rajeev M, Wallace M, Laver T, Milovancev M Can Vet J. 2023; 64(1):63-69.

PMID: 36593936 PMC: 9754142.


Evaluation of Tumor Grade and Proliferation Indices before and after Short-Course Anti-Inflammatory Prednisone Therapy in Canine Cutaneous Mast Cell Tumors: A Pilot Study.

Klahn S, Dervisis N, Lahmers K, Benitez M Vet Sci. 2022; 9(6).

PMID: 35737330 PMC: 9227510. DOI: 10.3390/vetsci9060277.


Optical coherence tomography for surgical margin evaluation of excised canine cutaneous and subcutaneous tumours.

Cheng E, Jennings R, Chen C, Biggo M, Erickson A, Dornbusch J Vet Comp Oncol. 2022; 20(4):836-845.

PMID: 35662386 PMC: 9796844. DOI: 10.1111/vco.12844.


Imatinib Mesylate for the Treatment of Canine Mast Cell Tumors: Assessment of the Response and Adverse Events in Comparison with the Conventional Therapy with Vinblastine and Prednisone.

Macedo T, de Queiroz G, Casagrande T, Alexandre P, Brandao P, Fukumasu H Cells. 2022; 11(3).

PMID: 35159380 PMC: 8834544. DOI: 10.3390/cells11030571.